Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06235008
Starting soon Observational

PAthwAy of Dyspneic patIent in Emergency in the North-east Region (North-East PArADIsE)

NCT06235008 · tracked via the Priya Life Science France tracker
Sponsor
Pr. Nicolas GIRERD
Phase
Observational
Started
2024-03-31
Last updated
2024-01-31

Condition(s) studied

Dyspnea

Study summary

This is an observational retrospective multi-center study in patients managed for acute dyspnea by Emergency department medical team.

The main aim of the study is to evaluate factors associated with mortality risks in patients managed for acute dyspnea by an Emergency department medical team, overall, as well as in subgroups of interest (male/female, age categories, mode of admission and comorbidities).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Man or women ≥ 18 years * Patients with acute dyspnea cared by a medical team of the emergencies of CHRU of Nancy, CHR Metz-Thionville and CH d'Epinal. Exclusion Criteria: * Cardiorespiratory arrest before medical management by the Emergency Department team * Adults under legal protection

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHRU Nancy France

More Pr. Nicolas GIRERD trials in France

Chronic Heart Failure - COngestion eValuation Recruiting
PAtient Treatment Analysis: Hospital and Wide-ranging Out-of-hospital Care Assessment Yields Insights Into Heart Failure Outcomes Recruiting
CHF-COV Reduced (Chronic Heart Failure With Reduced Ejection Fraction - COngestion eValuation) Recruiting
PAthwAy of Dyspneic patIent in Emergency in France Starting soon
Potassium Canrenoate in Brain-dead Organ Donors: Randomized Controlled Clinical Trial Active, not recruiting

Other trials for the same condition

Contactless Ultrasound Data Acquisition in Emergency Departments to Discriminate the Origin of Dyspnea and Chest Pain Starting soon
Evaluation of the Impact of Pleuropulmonary Ultrasound on the Diagnosis of Dyspnea Recruiting
Non-medicinal Technique and Dyspnea in Weaning Patients Starting soon
Prevalence, Determinants and Consequences of Dyspnea During Weaning in Critically Ill Obese Patients Recruiting
Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I Short of Breath?" Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06235008 on ClinicalTrials.gov ↗ ← All trials in France